iDirect Government | November 05, 2020
iDirect Government (iDirectGov), a leading provider of satellite communications to the military and government, today announced that the Evolution® platform has been enhanced with information assurance (IA) and cybersecurity as a part of a multi-layered approach to security. Two main technology advancements in Evolution 22.214.171.124 include SHIELD, a security service for remotes, and Communication Signal Interference Removal (CSIR™), a real-time streaming technology to mitigate interference. These enhancements are fully integrated across iDirectGov’s 9-Series satellite modems. To address vulnerabilities in satellite modems, SHIELD provides periodic IA security updates for the 9-Series modems. These remote-side packages are created using the same capability that the Defense Information Systems Agency's (DISA’s) Assured Compliance Assessment Solution (ACAS) recognizes. When installed, SHIELD addresses vulnerabilities based on the Common Vulnerabilities and Exposures (CVE) and Nessus ID database on the satellite modem and delivers IA posture across the SATCOM network.
Endo | December 24, 2021
Endo International plc today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas.
The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Texas and its subdivisions in exchange for a total payment of $63 million. The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims.
The Texas settlement resolves, among other things, claims against Endo's subsidiaries in two cases set for trial in Texas state court in 2022: County of Dallas v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77098, and County of Bexar v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77066. The plaintiffs in those cases agreed to sever Endo's subsidiaries from these upcoming trials pending implementation of the settlement.
The Company is continuing to litigate opioid claims not covered by its settlements and to pursue settlements that it believes are in its best interests while remaining focused on its primary goal of achieving a global settlement. At the same time, Endo is exploring other strategic alternatives, and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement. Endo cannot speculate on the likelihood, nature or timing of any outcome.
About Endo International plc
Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.
Teal | September 04, 2020
Teal today announced the public launch and immediate availability of Golden Eagle, a new US-made commercial drone system that provides aerial surveillance and awareness through scalable, secure, and rugged technology. Designed and manufactured entirely in the US to ensure the highest levels of data security and performance, Teal already has pilot programs running at Fortune 500 companies, as well as many government agencies. Golden Eagle serves as a dual-use platform and was recently selected as an approved system for the Department of Defense and Federal Government as part of DIU’s Blue sUAS Project and will soon be available on the GSA schedule.